CliffBio
small molecule

INVEGA SUSTENNA

PALIPERIDONE PALMITATE

Loss of exclusivityJanuary 2031latest FDA-listed patent expiry
CompanyJanssen Pharmaceuticals →View the full company profile on CliffBio

Drug detail

Brand nameINVEGA SUSTENNA
Active ingredientPALIPERIDONE PALMITATE
Strength39MG/0.25ML (39MG/0.25ML)
Dosage formSUSPENSION, EXTENDED RELEASE
RouteINTRAMUSCULAR
ModalitySmall molecule
FDA approvalJuly 2009
Marketing statusRX

Listed patents

PatentExpiresType
9439906January 2031use U-2757

More from Janssen Pharmaceuticals

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

INVEGA SUSTENNA patent cliff — loss of exclusivity January 2031 | CliffBio